Nautilus Biotechnology (NAUT) investor relations material

Industry context and technology overview

• Proteomics is the next frontier after genomics, as proteins are the main functional molecules in cells and are key drug targets, but current tools lack sensitivity and reproducibility for comprehensive measurement.

• The company is developing a novel benchtop platform to enable comprehensive, reproducible, and sensitive proteome analysis, aiming to make proteomics accessible to any biologist.

• Current gold-standard workflows rely on mass spectrometry, which is complex and fails to capture the full proteome, leaving significant gaps in drug discovery and diagnostics.

Platform applications and customer value

• The platform supports two main applications: broadscale proteome measurement and targeted proteoform assays, addressing key pain points in drug development and diagnostics.

• Broadscale analysis offers higher sensitivity and reproducibility, enabling detection of more proteins and rare biomarkers compared to existing technologies.

• Proteoform assays, such as the Tau assay for neurodegeneration, can measure hundreds of protein forms, providing unprecedented biological insights.

• Early access collaborations include studies on neurodegenerative and oncology markers, with a roadmap to expand the proteoform portfolio.

Recent milestones and scientific validation

• The instrument was publicly demonstrated for the first time at the US HUPO conference, marking a significant step in community engagement.

• Early access for proteoform assays is underway, with general availability and broadscale launch targeted for late this year and early next year.

• Validation studies on the Tau assay showed high reproducibility and accuracy, with variability as low as 5%, far exceeding industry norms.